EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons

Kohei Omachi iD, Joseph J Porter, John D Lueck, Jeffrey H Miner iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0330804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Kohei Omachi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Collagen Type IV, Codon, Nonsense, RNA, Transfer, Protein Biosynthesis. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alport syndrome is caused by variants in COL4A3 , COL4A4 , or COL4A5 , which encode the α3α4α5 chains of type IV collagen. These variants result in defects in the glomerular basement membrane (GBM) and impaired kidney function. Nonsense variants result in truncated proteins lacking the NC1 domain, thereby preventing proper GBM assembly and function and causing the most severe forms of the disease. Restoring full-length protein expression represents a potential therapeutic strategy for Alport syndrome and related disorders. Anticodon-edited transfer RNAs (ACE-tRNAs), which promote premature termination codon (PTC) readthrough, have shown promise in diseases such as cystic fibrosis, but their application in Alport syndrome remains unexplored. To assess the potential of ACE-tRNAs for PTC readthrough of COL4A5 nonsense variants, we employed a C-terminal NanoLuc-fused COL4A5 reporter system in which luminescence is produced only upon full-length protein translation. We introduced ACE-tRNAs into HeLa and 293T cells expressing one of four COL4A5 nonsense variants ( S36X, R1563X, S1632X, and R1683X ) identified in patients with X-linked Alport syndrome. Readthrough efficiency was evaluated via NanoLuc luminescence and western blotting. Furthermore, we assessed the efficiency of ACE-tRNA-restored α3α4α5 heterotrimer formation using a split NanoLuc-based assay. Our results show that application of ACE-tRNAs led to restored C-terminal luminescence across all four COL4A5 nonsense variants, indicating successful readthrough and full-length translation. Moreover, the restored COL4A5 proteins formed α3α4α5 heterotrimers. These findings support ACE-tRNA-mediated nonsense suppression as a promising therapeutic strategy for Alport syndrome, with the potential to restore GBM integrity in patients harboring nonsense variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Collagen Type IVCodon, NonsenseRNA, TransferProtein BiosynthesisHumansNephritis, HereditaryHeLa CellsHEK293 Cells

Substanzen

Collagen Type IVCodon, NonsenseCOL4A5 protein, humanRNA, Transfer

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Laboratory for Tissue Microenvironment, RIKEN Center for Biosystems Dynamics Research (BDR), Kobe, Hyogo, Japan.
  • Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
  • Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
  • Center for RNA Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.

ORCID-Profile: Kohei Omachi, Jeffrey H Miner

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Japan Society for the Promotion of Science
  • Cell Science Research Foundation
  • JST ACT-X
  • Cystic Fibrosis Foundation Therapeutics
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Omachi, K., Porter, J. J., Lueck, J. D., & Miner, J. H. (2025). Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons. PLOS One. https://doi.org/10.1371/journal.pone.0330804

Vancouver

Omachi K, Porter JJ, Lueck JD, Miner JH. Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons. PLOS One. 2025. doi:10.1371/journal.pone.0330804

BibTeX
@article{Omachi2025,
  author = {Omachi, Kohei and Porter, Joseph J and Lueck, John D and Miner, Jeffrey H},
  title = {Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0330804}
}
Kostenlos starten →